Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
6
|
| pubmed:dateCreated |
1995-3-23
|
| pubmed:abstractText |
A group of 31 oncohaemopathic patients (17 male, mean age 44 +/- 6 years), diagnosed as having primary deep fungal infection involving the lungs, were retrospectively evaluated. When infection was suspected on a clinical basis the major associated risks for death were the duration of bone marrow aplasia (12 +/- 7 versus 21 +/- 6 days, P < 0.001), increase in white blood cells and, in particular, prolonged granulocytopenia (11 +/- 5 versus 24 +/- 8 days, P < 0.001) when survivors were compared with patients, who died. Our therapeutic empirical approach was based on the association of i.v. amphotericin B, 1 mg kg-1 day-1, with oral 5-fluorocytosine (5-FC) 150 mg kg-1 day-1. Only 9 subjects received combination therapy for more than 7 days. For majority of them, oral 5-FC was interrupted because of altered compliance or sustained liver damage. A chi 2 test for independent parameters showed (P = 0.0021) a concentration of deaths among patients who received amphotericin B alone (15/22); none of the patients treated with amphotericin B + 5-FC (9 cases) died. Results generally suggest that a more favourable outcome was statistically associated with empirical antifungal combination therapy in deep fungal infection, although both treatment regimens showed effectiveness in terms of survival. Nevertheless the low 5-FC compliance and the small sample do not indicate the safe use of this drug in a large population.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Nov
|
| pubmed:issn |
0941-4355
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
2
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
385-8
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:7858932-Adolescent,
pubmed-meshheading:7858932-Adult,
pubmed-meshheading:7858932-Amphotericin B,
pubmed-meshheading:7858932-Aspergillosis,
pubmed-meshheading:7858932-Aspergillus,
pubmed-meshheading:7858932-Bronchoalveolar Lavage Fluid,
pubmed-meshheading:7858932-Cryptococcus,
pubmed-meshheading:7858932-Drug Therapy, Combination,
pubmed-meshheading:7858932-Female,
pubmed-meshheading:7858932-Flucytosine,
pubmed-meshheading:7858932-Humans,
pubmed-meshheading:7858932-Lung Diseases, Fungal,
pubmed-meshheading:7858932-Lymphoproliferative Disorders,
pubmed-meshheading:7858932-Male,
pubmed-meshheading:7858932-Middle Aged,
pubmed-meshheading:7858932-Mycoses,
pubmed-meshheading:7858932-Prognosis,
pubmed-meshheading:7858932-Retrospective Studies,
pubmed-meshheading:7858932-Risk Factors,
pubmed-meshheading:7858932-Survival Rate
|
| pubmed:year |
1994
|
| pubmed:articleTitle |
Association therapy as a prognostic factor in deep fungal infection complicating oncohaematological diseases.
|
| pubmed:affiliation |
Internal Medicine Department, University of Milan, S. Gerardo Hospital, Monza, Italy.
|
| pubmed:publicationType |
Journal Article
|